CANO:NYE-Cano Health Inc (USD)

COMMON STOCK | Medical Care Facilities | NYE

Last Closing Price

USD 5.12

Change

0.00 (0.00)%

Market Cap

USD 2.49B

Volume

2.71M

Avg Analyst Target

USD 9.00 (+75.78%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CANO Stock Forecast & Price:
Based on the Cano Health Inc stock forecasts from 7 analysts, the average analyst target price for Cano Health Inc is USD 9.00 over the next 12 months. Cano Health Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cano Health Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Cano Health Inc’s stock price was USD 5.12. Cano Health Inc’s stock price has changed by -16.61% over the past week, -4.30% over the past month and -52.46% over the last year.

About Cano Health Inc (CANO:NYE)

Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare provider ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCA HCA Holdings Inc

N/A

USD62.83B 10.45 7.40
FMS Fresenius Medical Care Corpora..

N/A

USD11.10B 13.48 7.04
AGL agilon health Inc

N/A

USD9.61B N/A -90.52
DVA DaVita HealthCare Partners Inc

N/A

USD8.44B 11.40 8.75
UHS Universal Health Services Inc

N/A

USD8.17B 11.53 7.99
CHE Chemed Corp

N/A

USD7.31B 27.34 17.61
THC Tenet Healthcare Corporation

N/A

USD7.23B 8.05 5.67
OSH Oak Street Health Inc

N/A

USD6.97B N/A -16.77
EHC Encompass Health Corp

N/A

USD5.37B 16.46 8.72
AMN AMN Healthcare Services Inc

N/A

USD4.94B 11.54 7.42

ETFs Containing CANO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.54% 14% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.54% 14% F 7% F
Trailing 12 Months  
Capital Gain -52.46% 18% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.46% 14% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.57% 23% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.57% 18% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 20.13% 77% C+ 55% F
Risk Adjusted Return -42.57% 14% F 8% F
Market Capitalization 2.49B 50% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.85 60% D- 30% F
Price / Cash Flow Ratio -19.36 91% A- 90% A-
EV/EBITDA 36.93 9% F 5% F
Management Effectiveness  
Return on Equity -9.13% 33% F 16% F
Return on Invested Capital -19.44% 23% F 8% F
Return on Assets -3.51% 18% F 10% F
Debt to Equity Ratio N/A 5% F 0% N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.32 45% F 17% F
Short Percent 17.63% 9% F 24% F
Beta 1.64 30% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector